New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond

Tomislav Kostyanev, Marc J.M. Bonten, Herman Goossens

Source: Eur Respir Monogr 2017; 75: 289-301

Journal Issue: Anti-infectives and the Lung

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Tomislav Kostyanev, Marc J.M. Bonten, Herman Goossens. New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond. Eur Respir Monogr 2017; 75: 289-301

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Management of drug resistant pulmonary TB. New problems and perspectives Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
New and repurposed drugs Source: Eur Respir Monogr 2018; 82: 179-204 Year: 2018
Management of COVID-19: Drugs anti-virals Source: ERS Course 2021 - COVID-19: State of the art Year: 2021
New technologies of corrections hemithorax in treatment of pulmonary tuberculosis Source: International Congress 2016 – Open problems in thoracic surgery Year: 2016
New horizons in ventilator development Source: ERS Course 2018 - Noninvasive ventilation: advanced Year: 2018
Research in respiratory medicine: New approaches in genetic diseases Source: ERS Summit on priorities in respiratory medicine 2011 Year: 2011
New Drugs for COPD: the current status Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016
New frontiers in the management of asthma Source: International Congress 2017 – State of the art session: "Paediatric" Year: 2017
Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
New targets for drug development in asthma Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008
New and repurposed drugs for MDR-TB patients Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence Year: 2017
Phenotypes of symptomatic airways disease in China and New Zealand Source: Eur Respir J, 50 (6) 1700957; 10.1183/13993003.00957-2017 Year: 2017
New definition of pulmonary rehabilitation Source: Annual Congress 2012 - The updated ATS/ERS statement on pulmonary rehabilitation - update from the ATS/ERS Task Force Year: 2012
New horizons in bronchiectasis Source: International Congress 2017 – Bronchiectasis: from guidelines to real life Year: 2017